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A B S T R A C T
Purpose
The Veterans Affairs (VA) healthcare system treats approximately 3% of patients with cancer in
the United States each year. We measured the quality of nonmetastatic colorectal cancer (CRC)
care in VA as indicated by concordance with National Comprehensive Cancer Network practice
guidelines (six indicators) and timeliness of care (three indicators).
Patients and Methods
A retrospective medical record abstraction was done for 2,492 patients with incident stages
I to III CRC diagnosed between October 1, 2003, and March 31, 2006, who underwent definitive
CRC surgery. Patients were treated at one or more of 128 VA medical centers. The proportion
of patients receiving guideline-concordant care and time intervals between care processes
were calculated.
Results
More than 80% of patients had preoperative carcinoembryonic antigen determination (ie,
stages II to III disease) and documented clear surgical margins (ie, stages II to III disease).
Between 72% and 80% of patients had appropriate referral to a medical oncologist (ie, stages
II to III disease), preoperative computed tomography scan of the abdomen and pelvis (ie,
stages II to III disease), and adjuvant fluorouracil-based chemotherapy (ie, stage III disease).
Less than half of patients with stages I to III CRC (43.5%) had a follow-up colonoscopy 7 to 18
months after surgery. The mean number of days between major treatment events included the
following: 26.6 days (standard deviation [SD], 38.2; median, 20 days) between diagnosis and
initiation of treatment (in stages II to III disease); 64.9 days (SD, 54.9; median, 50 days) between
definitive surgery and start of adjuvant chemotherapy (in stages II to III disease); and 444.1 days
(SD, 182.1; median, 393 days) between definitive surgery and follow-up colonoscopies (in stages
I to III disease).
Conclusion
Although there is opportunity for improvement in the area of cancer surveillance, the VA performs
well in meeting established guidelines for diagnosis and treatment of CRC.
J Clin Oncol 28:3176-3181. © 2010 by American Society of Clinical Oncology
INTRODUCTION
The Veterans Affairs (VA) healthcare system treats
approximately 3% of patients with cancer in the
United States (eg,  43,000 people in 2005). As with
the rest of the country,1,2 CRC is the third most
common cancer in VA. There were greater than
4,600 new occurrences of CRC entered onto the VA
Central Cancer Registry in 2005 (11% of VA can-
cer occurrences).
As part of VA’s focus on quality improvement,3-7
a widespread pilot of improving and measuring the
quality of VA cancer care, with a focus on CRC,
began in the fall of 2005.8-10 The purpose of this
article is to describe the quality of CRC care in VA by
measuring concordance with National Comprehen-
sive Cancer Network (NCCN) guidelines11,12 and
the timeliness with which cancer care is provided.
PATIENTS AND METHODS
Data were abstracted from the VA electronic health record
(EHR) for a sample of 2,492 patients with nonmetastatic
CRC diagnosed between October 1, 2003, and March 31,
2006. Initial analyses done for the VA Office of Quality and
Performance (OQP) were determined to be for quality
improvement purposes according to the Durham VA
Medical Center (VAMC) institutional review board (IRB)
chairperson. Subsequent analyses were done under the
approval of the Durham VAMC IRB.
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Data Source
Between July and August 2007, a one-time, special, chart-abstraction
study was conducted for the VA External Peer Review Program (EPRP).13
Abstraction was done by the EPRP contractor, West Virginia Medical Insti-
tute, under the auspices of VA OQP to assess the quality of CRC care. Abstrac-
tors accessed the medical record remotely (off site) to collect data on care
provided to individual patients across VA. Demographic information for 87%
of the sample included in the VA Central Cancer Registry was obtained from
the registry.
Patients
Patient identification was based on a search algorithm aimed at defining
a representative sample of VA patients with CRC diagnosed between October
1, 2003, and March 31, 2006, by utilizing administrative diagnosis, procedure,
and encounter data stored in the VA Decision Support System (a centralized
VA data system).14
Eligible patients had an International Classification of Disease (9th revi-
sion) code for colon and/or rectal cancer15 in VA administrative databases
between 3 months before and 3 months after the diagnosis time period for the
study. In addition, eligible patients had a clinic visit, procedure, or pathology
report in VA corresponding to one or more the following combinations of
medical services between 3 months prior and 3 months after the diagnosis time
period for the study: medical oncology plus radiation oncology, surgery, hos-
pice, pathology, gastroenterology, and/or colonoscopy; radiation oncology
only; surgery plus medical oncology, radiation oncology, hospice, pathology,
gastroenterology, and/or colonoscopy; hospice only; or pathology plus medi-
cal oncology, radiation oncology, surgery, and/or hospice. These combina-
tions of services could have occurred in any temporal order.
To be included in the final analytic data set, patients had to meet the
following additional inclusion criteria: stages I to III CRC; incident occurrence
(ie, initial diagnosis of CRC during the study period); and receipt of definitive
surgery for CRC. Definitive surgery was defined as a surgical intervention
directly aimed at resecting the CRC, such as a partial colectomy. Diagnosis
dates were based on the date of a signed pathology report that indicated
diagnosis of invasive CRC (including staging information). If a complete
pathology report was not available to the chart abstractor (eg, may have been
the result of remote nature of chart abstraction and does not necessarily imply
that pathology reports were not available during care), the date of the earliest
physician documentation of the diagnosis was used. A surgical pathology
report date was recorded for all patients included in this study. However,
precise contents of those reports were not recorded in the data set.
Quality Indicators
Six quality indicators were based on the 2003 (ie, first year of patient
inclusion) versions of the NCCN colon and rectal cancer guidelines.11,12
NCCN guidelines are based on evidence when available and consensus opin-
ion otherwise, so that a comprehensive treatment algorithm is developed.16 All
NCCN-based quality indicators used in this study are considered to have an
evidence base and have uniform NCCN guideline-panel consensus (at least
NCCN evidence category 2A).17,18 In addition to the NCCN guideline-based
measures, three timeliness indicators were developed. Although there is only
limited evidence that timeliness of care impacts disease outcomes of CRC
treatment,19 there is general consensus among oncology societies that timeli-
ness of cancer care is an important indicator of quality.20
Specific quality indicators for guideline concordance include the follow-
ing: preoperative computed tomography (CT) scan, preoperative carcinoem-
bryonic antigen (CEA), clear surgical margins, referral to a medical oncologist,
FU-based chemotherapy, and surveillance colonoscopy.
Preoperative CT scan. Documented preoperative CT scan of the abdo-
men and pelvis (or patient refusal of CT scan) for patients with stages II to III
CRC undergoing definitive surgical resection is available. Current NCCN
guidelines also recommend a CT scan of the chest.17,18 However, this recom-
mendation was not in place during the entire study period.
Preoperative CEA. Preoperative CEA determination for patients with
stages II to III CRC undergoing definitive surgical resection is documented.
CEA determination for CRC is included in American Society of Clinical
Oncology (ASCO) evidence-based guidelines.21,22
Clear surgical margins. Documentation of clear surgical margins for
patients with stages II to III CRC undergoing definitive surgical resection
is available.
Referral to a medical oncologist. Documented referral to a medical on-
cologist (or documented reason why not) for patients with stages II to III CRC
is available.
Fluorouracil-based chemotherapy. Adjuvant (postoperative) fluoroura-
cil (FU) –based therapy or capecitabine after definitive resection of stage III
CRC (or documented reason why not) is documented. Within current NCCN
CRC guidelines, only use of FU-based chemotherapy for patients with stage III
disease is specifically labeled as being based on NCCN category-1 evidence (ie,
high level of evidence [eg, randomized controlled trials] and uniform
NCCN consensus).17,18
Surveillance colonoscopy. Surveillance colonoscopy within 7 to 18
months after definitive surgery for patients with stages I, II, and III CRC with
documentation of no preoperative obstructing lesion is documented. To be
included in the calculation, a patient had to survive at least 1 year after
surgery. The 2003 and subsequent NCCN guidelines11,12 and current joint
guidelines of the American Cancer Society and major gastroenterology
societies23 recommend that colonoscopies occur within 1 year after surgery.
However, the 2005 ASCO guideline recommending surveillance colonoscopy
within 3 years of surgery has not been updated.24 For this study, 7 months was
used as a minimum, because colonoscopies performed sooner than 7 months
might not be intended primarily for surveillance, and 18 months was chosen
because surveillance colonoscopies may not occur exactly within 1 year.
Specific quality indicators for the timeliness of care include the following:
diagnosis to initiation of treatment, surgery to the initiation of adjuvant chem-
otherapy, and surgery to surveillance colonoscopy.
Diagnosis to initiation of treatment. Days from diagnosis to initiation of
treatment—including definitive surgery, chemotherapy, and/or radiation
therapy—were measured for patients with stages II to III CRC. For patients
with rectal cancer, it is possible for a definitive diagnosis to be made after
initiation of therapy. NCCN guidelines suggest that, for some stages II to III
rectal cancers, neoadjuvant (ie, preoperative) radiation therapy is warranted.
In occurrences for which a definitive pathologic diagnosis of invasive cancer
(with staging information) is not made until the time of surgery, the interval
from diagnosis to treatment may be represented as a negative number. This
occurred for 14.3% of patients who contributed data to the quality indicator.
Surgery to the initiation of adjuvant chemotherapy. Days from definitive
surgery to initiation of adjuvant (ie, postoperative) chemotherapy treatment
for patients with stages II to III CRC were measured. Although adjuvant
chemotherapy is not necessarily indicated for all patients with stage II dis-
ease,11,12 we are assuming that patients with stage II disease who receive
adjuvant chemotherapy should begin chemotherapy as soon as clinically ap-
propriate. As a result, this measure utilized data for patients with stage II
disease who have both a recorded surgery and chemotherapy start date.
Surgery to surveillance colonoscopy. Days from definitive surgery to
surveillance colonoscopy in patients with stages I, II, and III CRC with docu-
mentation of no preoperative obstructing lesion were measured.
Data Analysis
We report the percentage of patients with CRC receiving care concor-
dant with clinical practice guidelines and the mean (standard deviation [SD])
and median (interquartile range) number of days between care events for
timeliness indicators. Because each chart abstraction represents at least 15
months of follow-up, 1-year (ie, 365-day), stage-specific mortality rates were
calculated. Results were combined for patients with colon cancer and rectal
cancer. SAS version 9.1.3 (SAS Institute, Cary, NC) was used for data manage-
ment and analyses.
RESULTS
Of 9,599 individual patients identified by the case-finding algorithm,
571 (5.9%) did not have a CRC diagnosis, and 4,640 (48.3%) had a
diagnosis outside of the 2.5-year study-diagnosis period. This would
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be expected, because the search algorithm allowed for codes 3 months
before or after the official study period, with the goal of capturing
patients diagnosed throughout the time period of interest. Of the
remaining 4,388 patients, 212 (4.8%) did not have a documented stage
in the VA EHR, 709 (16.2%) did not have a record of definitive CRC
surgery, and 517 (13.0%) did not have a documented diagnosis of
CRC. This would be expected, because some patients with CRC may
not have had an indication for surgery because of synchronous meta-
static disease or endoscopic removal of certain early-stage (ie, T0)
cancers. In addition, some CRC codes may have been included in
administrative data during the diagnostic process for patients who did
not have the disease. Of the remaining 2,896 patients, 119 with stage 0
(ie, noninvasive) disease and 285 with stage IV (ie, metastatic) disease
were not included in the final data set; 2,492 patients with stages I to III
disease remained who met all inclusion criteria.
Most patients were men (97.9%) and had a mean age of 68.3
years (SD, 10.4) at the time of diagnosis. Patients were treated at 128 of
the 153 VA medical centers. Stage-specific 1-year mortality rates in-
cluded the following: stage I, 4.9%; stage II, 5.9%; and stage III, 11.8%.
Table 1 describes patient characteristics.
Tables 2 and 3 detail quality-indicator results. More than 80% of
patients had preoperative CEA determination (by stages II to III,
82.8%; by documented clear surgical margins and stages II to III,
81.2%). Among 329 patients without clear margins, 207 had docu-
mentation that margins were not clear, the abstractor was not able to
determine status of margins for 118 patients, and the question answer
was missing in four patients. The majority of patients also had appro-
priate referral to a medical oncologist (in stages II to III, 77.5%),
adjuvant FU-based chemotherapy (in stage III, 73.5%), and preoper-
ative CT scan of the abdomen and pelvis (in stages II to III, 72.1%).
However, less than half of patients with stages I, II, or III disease
without a preoperative obstructing lesion (43.5%) had a follow-up
colonoscopy within 7 to 18 months of surgery.
The mean number of days between major treatment events in-
cluded the following: 26.6 days (SD, 38.2; median, 20 days) between
diagnosis and initiation of treatment, including surgery, radiotherapy,
or chemotherapy (in stages II to III); 64.9 days (SD, 54.9; median, 50
days) between definitive surgery and start of adjuvant chemotherapy
(in stages II to III disease who received adjuvant chemotherapy); and
444.1 days (SD, 182.1; median, 393 days) between definitive surgery
and follow-up colonoscopy (in patients with stages I, II, and III disease
Table 1. Characteristics of Patients in the Sample of Nonmetastatic
Colorectal Cancer
Characteristic
Patients (N  2,492)
No. No. Evaluated %
Ethnicity





















1-Year mortality by stage at
diagnosis
I 37 763 4.9
II 54 921 5.9
III 95 808 11.8
Abbreviation: SD, standard deviation.
Data were based on 2,480 patients with age information.
†Diagnoses were made between October 1, 2003, and March 31, 2006.
Table 2. Guideline Concordance Quality of Nonmetastatic Colorectal Cancer Care in the Veterans Health Administration





Preoperative CT scan of abdomen and pelvis prior
to definitive surgical resection
Stages II and III colorectal cancer 1,729 72.1
Preoperative CEA determination prior to definitive
surgical resection
Stages II and III colorectal cancer 1,729 82.8
Documented radial margins were free of tumor at
the time definitive surgical resection
Stages II and III colorectal cancer 1,725 81.2†
Referral to a medical oncologist Stages II and III colorectal cancer 1,729 77.5
Adjuvant FU or capecitabine administered after
definitive surgical resection
Stage III colorectal cancer 808 73.5
Surveillance colonoscopy within 7 to 18 months
after definitive surgical resection for patients
with documentation of no preoperative
obstructing lesion
Stages I, II, and III colorectal cancer with
no preoperative obstructing lesion
documented
1,259 43.5
Abbreviations: CT, computed tomography; CEA, carcinoembryonic antigen; FU, fluorouracil.
Margins question was missing with four patients.
†Of the 1.725 patients for whom the abstraction question pertaining to clear margins was answered, 1400 (81.2%) had documentation of clear margins, 207
(12.0%) had medical record indication that margins were not clear, and for 118 (6.8%) abstractors could not ascertain the margin status from the medical record.
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who had a follow-up colonoscopy). The standard deviation is larger
than the mean for diagnosis to initiation of treatment because treat-
ment could have been initiated before the official diagnosis date in
occurrences for which the definitive pathology report with final stag-
ing information followed neoadjuvant therapy. This neoadjuvant
therapy would generally have been based on an initial diagnosis made
by using a combination of information from a pathology report of
biopsy results and radiographic findings.12
DISCUSSION
With the exception of receiving follow-up colonoscopy within 7 to 18
months of definitive surgery, more than 72% of VA patients received
care that was guideline concordant for each diagnostic and therapeu-
tic measure.
Although direct comparisons with non-VA providers are not
available, the level of guideline concordance appears to at least be
similar to that of the private sector. The National Initiative for
Cancer Care Quality (NICCQ) evaluated 25 CRC quality measures
by using medical record abstraction and patient survey results in five
geographic regions among patients with stages II to III CRC diag-
nosed in 1998. They found that, overall, patients received guideline-
concordant care 78% of the time. Some NICCQ measures can be
obtained from medical records and, therefore, may be mapped to
quality indicators that we evaluated. For example, among patients
with CRC with non-T4 lesions who underwent resection, NICCQ
found that 85% had documentation of clear surgical margins.25 Sim-
ilarly, we found that 81% of patients undergoing surgery in VA had
this documentation. In addition, population-based reviews of patients
entered onto the California Cancer Registry and Surveillance, Epide-
miology, and End Results (SEER) –Medicare data set in the mid- to
late-1990s found rates of referral to a medical oncologist (75%)26 and
receipt of appropriate adjuvant chemotherapy (67%)27 similar to or
somewhat less than our results from VA between 2003 and 2006
(medical oncology referral for stages II to III, 78%; adjuvant FU-based
chemotherapy for stage III, 74%). A review of care provided by four
clinics affiliated with the University of South Florida Moffitt Cancer
Center in 2004 found that 57% of patients received preoperative/
prechemotherapy CEA testing,28 whereas we found that 83% of pa-
tients received this recommended evaluation in VA.
The area of the greatest opportunity for improvement in VA is
performance and documentation of timely colonoscopy surveillance.
Only 44% of patients without a preoperative obstructing lesion re-
ceived a surveillance colonoscopy documented in the medical record
within 7 to 18 months after surgery. When restricted to the more
stringent, 12-month postoperative colonoscopy recommendation re-
cently put forth by a multisociety task force,29 only 23% of VA patients
with CRC with nonobstructing lesions had documentation of appro-
priate postoperative colonoscopy surveillance. The NICCQ analysis
found 50% guideline-concordance for CRC surveillance.25 The Mof-
fitt analysis found that 43% of patients had a colon evaluation within
12 months of surgery.28 An important consideration, however, is that
during the study period NCCN guidelines recommended a 1-year
follow-up,11,12 whereas other societies recommended a 3-year follow-
up.24,30 This lack of agreement may have contributed to lower levels of
guideline concordance both within and outside VA.
A review of SEER-Medicare data from patients diagnosed from
2000 to 2001 found that 73.6% of CRC survivors had a least one
colonoscopy within 3 years of diagnosis.31 A similar analysis of 749
patients with stages I to III disease in our data set with at least 3 years of
follow-up from the time of diagnosis found that 60.9% had a least one
documented colonoscopy within 3 years of diagnosis.
Although the precise reason for lower levels of documented sur-
veillance is not known, there are quality improvement opportunities
for clinicians and health systems.32 Related efforts might focus on
improving the transition of care between specialties and primary care
(including use of care templates to guide physicians in the surveillance
process), better tracking and documentation of colonoscopies per-
formed outside VA, and increasing patient knowledge and participa-
tion in surveillance. Regarding improvement of follow-up of positive
fecal occult blood tests in VA, evidence points to the importance of
such quality improvement infrastructure (eg, measuring colonoscopy
supply and demand, creating system for patient tracking) and process
changes (eg, clarifying roles of different clinical services, revising
colonoscopy preparation education and protocols).33 These changes
represent ongoing efforts of VA facilities to improve the provision of
colonoscopies. Evidence concerning system failures related to the
provision of breast cancer care outside VA additionally indicates the
importance of addressing system processes, such as the interaction
between treating specialties.34
Table 3. Timeliness of Nonmetastatic Colorectal Cancer Care in the Veterans Health Administration




Mean SD Median IQR
Days from diagnosis to initiation of
initiation of treatment (i.e.
surgery, chemotherapy, and/or
radiation therapy)
Stages II and III colorectal cancer 1,729 26.6 38.2 20.0 37
Days from definitive surgical resection
to start of adjuvant chemotherapy
Stages II and III colorectal cancer 767 64.9 54.9 50.0 35
Days from definitive surgical resection
to surveillance colonoscopy for
colonoscopies performed at least
7 months after surgical resection
Stages I, II, and III colorectal cancer with
no preoperative obstructing lesion
documented
644 444.1 182.1 393.0 166
Abbreviation: IQR, interquartile range.
Quality of VA Colorectal Cancer Care
www.jco.org © 2010 by American Society of Clinical Oncology 3179
Although specific standards of timeliness of care are not available,
the 2008 joint quality measures of ASCO and NCCN suggest that
patients should receive adjuvant chemotherapy within 4 months of
colon cancer diagnosis and 8 months of rectal cancer diagnosis.20
Delay in initiation of adjuvant chemotherapy has been associated with
both increased cancer-specific and all-cause mortality among patients
with stage III colon cancer.19 For this study, the mean number of days
between surgery and adjuvant chemotherapy was 64 (SD, 54.9; me-
dian, 50 days). Among patients with adjuvant chemotherapy start
dates available, 93.0% began the process within 120 days of surgery.
Limited comparison data indicate that VA has timeliness of care
consistent with other healthcare systems. A Canadian study of 3,510
patients with CRC diagnosed from 1993 to 2000 found a median
number of 19 days between diagnosis and surgery.35 This compares
with 20 days for VA. On the basis of information in the SEER-
Medicare database, approximately 4,382 patients with stage III colon
cancer older than 65 years who were diagnosed from 1992 to 1999 and
received adjuvant chemotherapy; 26%, 55%, 10%, and 9% received
chemotherapy within 1, 1 to 2, 2 to 3, and greater than 3 months of
surgery, respectively.19 This compares with 11%, 52%, 22%, and 13%
of 767 patients with stages II to III CRC receiving chemotherapy who
got the treatment within 1, 1 to 2, 2 to 3, and greater than 3 months of
surgery, respectively, in this study.
This analysis has some important limitations. It was based on a
review of the VA EHR. Although information from across VA could
be accessed, information on care delivered outside VA (eg, colonos-
copies provided by non-VA providers, including those paid for by VA)
that was not captured in the EHR or was only noted in a paper medical
record would not have been available to the abstractor. Remote EHR
access also may have limited the ability of abstractors to see scanned
documents. In addition, patients with care patterns different from the
case-finding algorithm would not have been included. Finally, the
criterion requiring that patients had definitive surgery meant that
the numbers of patients with stage IV disease in the data set was
insufficient to assess the quality of care provided to patients with
stage IV disease. Despite these limitations, quality of care in and
outside VA appears similar.
Because of the potential limitation of remote abstraction, VA
OQP offered each Veterans Integrated Service Network (VISN) the
opportunity to review cases of patients for whom there was not docu-
mentation of receiving guideline-concordant care on the basis of a
given quality indicator and all patients contributing data to timeliness
measures. This article presents the prereview results, because VISNs
were not mandated to review the data. As a result, the pre-VISN review
provides a more consistent assessment of the quality of VA CRC care.
Conclusions of the manuscript were not changed by the minor
changes in the data after VISN review.
CRC represents an important condition and may serve as a proxy
for the overall quality of cancer care. Via indirect comparison, the VA
compares favorably with non-VA health systems in the delivery of
CRC diagnostic and therapeutic measures. There may be opportuni-
ties for improvement in CRC surveillance.
In the past decade and a half, VA has become a leader in provid-
ing quality health care.36-38 By measuring the quality of CRC and
developing tools that can be used to respond to quality gaps, VA
has become a national leader in the cancer care quality improve-
ment process.
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